Metabolic Medicine · GLP-1 Therapy

Ozempic, Wegovy & Mounjaro Consultation in Delhi

GLP-1 medicines — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — are weekly injections that lower appetite, blood sugar and weight, typically 10–20% of body weight over a year under supervision. They need a prescribing physician to titrate the dose, manage nausea, and monitor thyroid, pancreas and kidney safety.

Supervised GLP-1 therapy for diabetes and obesity — Ozempic (semaglutide), Wegovy, Mounjaro (tirzepatide) and Rybelsus — prescribed and monitored by Dr. Sanjay Sachdev (MBBS, MNAMS) at Friends Colony and Maharani Bagh, South Delhi.

WhatsApp the ClinicCall +91 98110 78388

What GLP-1 medicines actually do

GLP-1 (and dual GIP/GLP-1) receptor agonists slow gastric emptying, blunt appetite, improve insulin sensitivity and lower blood glucose. The result, in eligible patients, is meaningful weight loss (10–22% with tirzepatide in trials), better HbA1c, lower blood pressure, improved lipids and reduced cardiovascular risk.

How we prescribe and monitor

We start with a full assessment — history, contraindication screen (personal/family medullary thyroid cancer, pancreatitis, severe gastroparesis), baseline labs and weight metrics. Doses are titrated slowly to minimise side effects. Follow-ups review tolerance, weight trend, HbA1c, lipids, liver and kidney function.

Side effects we manage

Nausea, early satiety, constipation or loose stools, occasional reflux. Most settle within weeks of each dose step. We adjust titration speed, hydration, fibre, meal timing and antacid use as needed — and pause or switch agents if needed.

Who this is for

Adults with Type 2 diabetes (uncontrolled on metformin), pre-diabetes with significant weight, obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with comorbidities, and patients seeking a structured second opinion on whether GLP-1 therapy is right for them.

Frequently asked

6 answers
Where can I consult about Ozempic or Mounjaro in Delhi?
Dr. Sanjay Sachdev (MBBS, MNAMS) consults on GLP-1 therapy — Ozempic (semaglutide), Wegovy, Mounjaro (tirzepatide) and Rybelsus — at his Friends Colony and Maharani Bagh clinics in South Delhi.
Are Ozempic and Mounjaro safe?
Both are well-studied, FDA-approved drugs with a clear safety profile when prescribed and monitored correctly. The most common side effects are gastrointestinal (nausea, reflux) and usually settle with dose titration. We screen for contraindications before starting.
What's the difference between Ozempic, Wegovy, Mounjaro and Rybelsus?
Ozempic and Wegovy are both semaglutide (Ozempic licensed for diabetes, Wegovy for obesity). Mounjaro is tirzepatide — a dual GIP/GLP-1 agonist with stronger weight-loss data. Rybelsus is oral semaglutide. Choice depends on goal, tolerability, availability and cost.
How long do I need to stay on a GLP-1?
Obesity is a chronic condition, so most patients benefit from longer-term use. We plan duration individually — some patients taper after reaching a stable weight with an intensive lifestyle programme; others continue at a maintenance dose.
What's the cost and availability in India?
Mounjaro (tirzepatide) is now available in India through Lilly; Ozempic and Wegovy availability varies. We discuss legitimate pharmacy sources, avoid grey-market vials, and tailor the regimen to what's reliably available.
Do I still need to diet and exercise?
Yes — the medicine reduces appetite and improves metabolic control, but lean-mass preservation, protein intake, strength training and sleep determine long-term outcome. Lifestyle isn't optional, it's what makes the result durable.

Also serving these South Delhi neighbourhoods

Related searches

GLP-1 Clinic DelhiMounjaro Price IndiaOzempic Price IndiaMounjaro vs OzempicMounjaro Side EffectsOzempic Side EffectsWegovy & RybelsusWeight Loss DoctorOzempic Doctor DelhiMounjaro Doctor Delhi
South Delhi

Looking for the best physician in South Delhi?

Meet Dr. Sachdev →

Book a consultation

Consultations are by appointment at Friends Colony East and Maharani Bagh, South Delhi.

CallWhatsApp